HomeFileStructural heart disease

Structural heart disease

View Category

Sponsored Symposia

SOLACI-CACI 2021 | Current Controversies in Post-TAVR CORONARY ACCESS – Medtronic Symposium

✔️ MEDTRONIC Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Current Controversies in Post-TAVR CORONARY ACCESS.  👨‍🏫 Program:...
solaci -
Learn More
Antiplatelet

ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation

The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when...
solaci -
Learn More
Structural Heart Disease

ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic...
solaci -
Learn More
Structural heart disease

New Markers of Aortic Stenosis Define Asymptomatic Patients

Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of...
solaci -
Learn More
Institutional News

SOLACI Webinar | Minimalist TAVI III Summit: A Meeting with the Experts

solaci -
Learn More
Valvular Aortic Valve

TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is...
solaci -
Learn More
Structural heart disease

Direct TAVR vs. Predilation: Potential Cost of a Simpler Procedure

Does simplifying TAVR involve a cost? At least for low-risk patients included in the PARTNER 3, the...
solaci -
Learn More
Antithrombotic Anticoagulants

European Consensus on Antithrombotic Management in TAVR

All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter...
solaci -
Learn More